Chantelle Hudson
About Chantelle Hudson
Chantelle Hudson is a Senior Principal Scientist at BenevolentAI with extensive experience in cancer research and CRISPR technology.
Current Role at BenevolentAI
Chantelle Hudson is currently serving as the Senior Principal Scientist at BenevolentAI. In this role, she leverages her extensive expertise in molecular biology and cancer research to contribute to the company's innovative drug discovery platforms. Her responsibilities likely involve guiding research projects, analyzing complex biological data, and developing advanced scientific strategies to facilitate breakthroughs in medicine.
Professional Background at BenevolentAI
Chantelle Hudson has a deep-rooted career at BenevolentAI, having held multiple roles over the years. She began as an Exploratory Scientist from 2017 to 2019 in London, United Kingdom, focusing on early-stage research and development. She was then promoted to Principal Scientist, serving from 2019 to 2021. In her current role as Senior Principal Scientist, she continues to drive scientific discovery and innovation.
Previous Experience at Horizon Discovery
Before her tenure at BenevolentAI, Chantelle Hudson worked at Horizon Discovery as a Senior Research Scientist from 2016 to 2017 in Cambridge, United Kingdom. During her time at Horizon Discovery, she managed and developed CRISPR/Cas9 and CRISPRi/Cas9 screens to identify novel targets for cancer therapy. Her work focused on leveraging CRISPR technology to advance cancer research and therapeutic development.
Educational Background
Chantelle Hudson holds a PhD in Molecular Biology with a focus on Transcription Factors from University College London, U. of London, where she studied from 2001 to 2005. Her foundational education in genetics was obtained at the University of Leicester, where she earned her BSc (Hons) 2:1 in Genetics from 1996 to 1999. Her academic training provided a strong basis for her subsequent research and professional achievements in the field of cancer biology.